Trial Profile
A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2018 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.